Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids.
Lipoprotein lipase (LPL) bound to the lumenal surface of vascular endothelial cells is responsible for the hydrolysis of triglycerides in plasma lipoproteins. Studies were performed to investigate whether human plasma lipoproteins and/or free fatty acids would release LPL which was bound to endothelial cells. Purified bovine milk LPL was incubated with cultured porcine aortic endothelial cells resulting in the association of enzyme activity with the cells. When the cells were then incubated with media containing chylomicrons or very low density lipoproteins (VLDL), a concentration-dependent decrease in the cell-associated LPL enzymatic activity was observed. In contrast, incubation with media containing low density lipoproteins or high density lipoproteins produced a much smaller decrease in the cell-associated enzymatic activity. The addition of increasing molar ratios of oleic acid:bovine serum albumin to the media also reduced enzyme activity associated with the endothelial cells. To determine whether the decrease in LPL activity was due to release of the enzyme from the cells or inactivation of the enzyme, studies were performed utilizing radioiodinated bovine LPL. Radiolabeled LPL protein was released from endothelial cells by chylomicrons, VLDL, and by free fatty acids (i.e. oleic acid bound to bovine serum albumin). The release of radiolabeled LPL by VLDL correlated with the generation of free fatty acids from the hydrolysis of VLDL triglyceride by LPL bound to the cells. Inhibition of LPL enzymatic activity by use of a specific monoclonal antibody, reduced the extent of release of 125I-LPL from the endothelial cells by the added VLDL. These results demonstrated that LPL enzymatic activity and protein were removed from endothelial cells by triglyceride-rich lipoproteins (chylomicrons and VLDL) and oleic acid. We postulate that similar mechanisms may be important in the regulation of LPL activity at the vascular endothelium.
Saxena
U
U
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032.
Witte
L D
LD
Goldberg
I J
IJ
D000818:Animals; D000911:Antibodies, Monoclonal; D001011:Aorta; D002417:Cattle; D002914:Chylomicrons / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000201:enzymology*; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology*; D006801:Humans; D007457:Iodine Radioisotopes; D007700:Kinetics; D008071:Lipoprotein Lipase / Q000276:immunology / Q000378:metabolism*; D008074:Lipoproteins / Q000097:blood / Q000494:pharmacology*; D008079:Lipoproteins, VLDL / Q000494:pharmacology; D008892:Milk / Q000201:enzymology; D019301:Oleic Acid; D009829:Oleic Acids / Q000494:pharmacology; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D013552:Swine; D014280:Triglycerides / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D002914:Chylomicrons; D005230:Fatty Acids, Nonesterified; D007457:Iodine Radioisotopes; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D009829:Oleic Acids; D014280:Triglycerides; D012710:Serum Albumin, Bovine; D019301:Oleic Acid; D008071:Lipoprotein Lipase